RTOG-0621

Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial

Principal Investigator

Mark Hurwitz

Status

Disease Site

Genitourinary [GU] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess whether the addition of androgen suppression therapy (AST) and docetaxel to adjuvant radiation therapy (ART) improves freedom from progression (FFP) as defined as PSA < 0.4 ng/ml, and no clinical failure (local-regional, or distant failure) at 3 years.

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Pathologically proven diagnosis of adenocarcinoma of the prostate meeting one of the following combinations:
 

 Gleason score > = 7 at the time of prostatectomy and PSA nadir > 0.2ng/ml;
 Gleason score > =  8 at the time of prostatectomy and T classification > = T3a.

Target Accrual

76